Nepstar Acquires Ningbo Xinshiji Pharmaceutical’s Drug Chain
This article was originally published in PharmAsia News
Executive Summary
Nepstar, China's largest drug retailer, has signed an agreement to acquire Ningbo Xinshiji Pharmaceutical's chain of 68 drugstores at 30 million yuan ($4.2 million). This represents Nepstar's first acquisition after its listing overseas. Ningbo Xinshiji's drug chain sales hit about 50 million yuan ($7 million) in 2007, ranking third in Ningbo, Zhejiang Province, according to 2006 statistics. After finalizing the transaction in March, Nepstar will become the biggest drug chain in Ningbo. A company official said that this acquisition marks Nepstar's first step toward integrating the retail chain drugstore; it will seek more targets nationwide to speed up its growth and market expansion. (Click here for more - Chinese Language)
You may also be interested in...
Nepstar Suspends Acquisition Of Wulin Drugstore
Nepstar Chain Drugstore has suspended its acquisition of Hangzhou Wulin Drugstore due to a lack of consensus on the terms of agreement. Sources reveal that the deal is worth about RMB 40 million and price was the key issue that stalls the process. After buying 68 drugstores under Ningbo Xinshiji Pharmaceutical's Drug Chain with RMB 30 million (PharmAsia News March 3, 2008) and Huirentang's 18 chain drugstores in Dongguan for RMB 2.3 million (PharmAsia News March 17, 2008) early this year, Nepstar was all set to acquire Wulin Drugstores. The firm aims to open 1,050 new shops by acquisition within 2008. However, the plan may derail due to high top-level management turnover that reflects the pressure to perform amidst its rapid expansion. (Click here for more - Chinese Language)
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.